Cargando…

A Decision Support Tool for Allogeneic Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: Acceptability and Usability Study

BACKGROUND: Individuals living with sickle cell disease (SCD) may benefit from a variety of disease-modifying therapies, including hydroxyurea, voxelotor, crizanlizumab, L-glutamine, and chronic blood transfusions. However, allogeneic hematopoietic stem cell transplantation (HCT) remains the only no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veludhandi, Anirudh, Ross, Diana, Sinha, Cynthia B, McCracken, Courtney, Bakshi, Nitya, Krishnamurti, Lakshmanan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JMIR Publications 2021
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587189/ https://www.ncbi.nlm.nih.gov/pubmed/34709190 http://dx.doi.org/10.2196/30093

Ejemplares similares

Primary caregiver decision-making in hematopoietic cell transplantation and gene therapy for sickle cell disease
por: Sinha, Cynthia B., et al.
Publicado: (2020)

Intraindividual pain variability and phenotypes of pain in sickle cell disease: a secondary analysis from the Pain in Sickle Cell Epidemiology Study
por: Bakshi, Nitya, et al.
Publicado: (2022)

Management of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic: A Qualitative Study
por: Sinha, Cynthia B., et al.
Publicado: (2019)

From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea
por: Sinha, Cynthia B., et al.
Publicado: (2018)

Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease
por: Bakshi, Nitya, et al.
Publicado: (2017)

Acute Chest Syndrome in Children with Sickle Cell Disease
por: Jain, Shilpa, et al.
Publicado: (2017)

Presence of pain on three or more days of the week is associated with worse patient reported outcomes in adults with sickle cell disease
por: Bakshi, Nitya, et al.
Publicado: (2018)

Assessment of Patient and Caregiver Attitudes and Approaches to Decision-Making Regarding Bone Marrow Transplant for Sickle Cell Disease: A Qualitative Study
por: Bakshi, Nitya, et al.
Publicado: (2020)

Hematopoietic Cell Transplantation for Sickle Cell Disease
por: Krishnamurti, Lakshmanan
Publicado: (2021)

Multimodal phenotyping and correlates of pain following hematopoietic cell transplant in children with sickle cell disease
por: Bakshi, Nitya, et al.
Publicado: (2023)

Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial
por: Krishnamurti, Lakshmanan, et al.
Publicado: (2019)

Patient and family experience with chronic transfusion therapy for sickle cell disease: A qualitative study
por: Hawkins, Lauren M., et al.
Publicado: (2020)

Pain catastrophizing is associated with poorer health-related quality of life in pediatric patients with sickle cell disease
por: Bakshi, Nitya, et al.
Publicado: (2018)

Quantitative sensory testing is feasible and is well-tolerated in patients with sickle cell disease following a vaso-occlusive episode
por: Bakshi, Nitya, et al.
Publicado: (2018)

Decision-making about gene therapy in transfusion dependent thalassemia
por: Quarmyne, Maa-Ohui, et al.
Publicado: (2022)

Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision
por: Creary, Susan, et al.
Publicado: (2015)

Sex and frequency of pain episodes are associated with acute pain trajectories in adolescents with sickle cell disease
por: Astles, Rachel, et al.
Publicado: (2023)

Home-Based Spirometry Telemonitoring After Allogeneic Hematopoietic Cell Transplantation: Mixed Methods Evaluation of Acceptability and Usability
por: Sheshadri, Ajay, et al.
Publicado: (2022)

Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease
por: Saraf, Santosh L., et al.
Publicado: (2019)

Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle Cell Disease: Design and Feasibility Study
por: Krishnamurti, Lakshmanan, et al.
Publicado: (2022)

Assessing Patient Preferences for Treatment Options for Pediatric Sickle Cell Disease: A Critical Review of Quantitative and Qualitative Studies
por: Katoch, Deeksha, et al.
Publicado: (2021)

Effects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility Study
por: Rodgers-Melnick, Samuel N, et al.
Publicado: (2022)

Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation
por: Stenger, Elizabeth O., et al.
Publicado: (2015)

Allogeneic hematopoietic stem cell transplantation to cure sickle cell disease: A review
por: Bhalla, Nishka, et al.
Publicado: (2023)

The role of the arginine metabolome in pain: implications for sickle cell disease
por: Bakshi, Nitya, et al.
Publicado: (2016)

Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin
por: Chiang, Kate Chander, et al.
Publicado: (2023)

Prevalence and predictors of chronic pain intensity and disability among adults with sickle cell disease
por: Matthie, Nadine, et al.
Publicado: (2020)

The hematopoietic saga of clonality in sickle cell disease
por: Stonestrom, Aaron J., et al.
Publicado: (2022)

Long-Term Effects of Allogeneic Hematopoietic Stem Cell Transplantation on Systemic Inflammation in Sickle Cell Disease Patients
por: de Azevedo, Júlia Teixeira Cottas, et al.
Publicado: (2021)

Awareness and Acceptance of Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Jazan Province, Saudi Arabia
por: Hurissi, Eman, et al.
Publicado: (2022)

The feasibility, acceptability, and usability of telehealth visits
por: Sinha Gregory, Naina, et al.
Publicado: (2023)

Choice of Donor Source and Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Sickle Cell Disease
por: Limerick, Emily, et al.
Publicado: (2019)

Effective sickle hemoglobin reduction by automated red cell exchange using Spectra Optia in three Emirati patients with sickle cell disease before allogeneic hematopoietic stem cell transplantation
por: Choi, Seung Jun, et al.
Publicado: (2018)

Role of Comorbidities in Optimizing Decision-Making for Allogeneic Hematopoietic Cell Transplantation
por: Sorror, Mohamed L., et al.
Publicado: (2010)

Association of genetic variation in COMT gene with pain related to sickle cell disease in patients from the walk-PHaSST study
por: Zhang, Yingze, et al.
Publicado: (2018)

Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation
por: Du, Wei, et al.
Publicado: (2018)

Allogeneic hematopoietic stem-cell transplantation for myelofibrosis
por: Zhang, Lining, et al.
Publicado: (2020)

Allogeneic Hematopoietic Cell Transplantation and Cellular Therapy
por: Kim, Hee-Je, et al.
Publicado: (2021)

Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases
por: Arnold, Staci D., et al.
Publicado: (2017)

Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children
por: Schoettler, Michelle, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ielv4433iqjcu5r6bakrm3puga